My five-month course of isotretinoin brought acne under control after years of unsuccessful treatment. As my skin improved, though, I developed problems I had not felt ready to handle. Dry mucous membranes, joint discomfort, changes in how I felt and persistent worry about possible consequences gradually became as much a part of treatment as watching the inflammation on my face subside.
I do not regret starting treatment. The result changed how I felt about my appearance. Looking back, I understand that conversations with a dermatologist need to cover the blood test results and the number of remaining lesions, as well as the physical and emotional demands of living through the course. Even an expected side effect can feel very different when you live with it every day.
Why I decided to start treatment
I was 26 when my dermatologist suggested considering isotretinoin. Acne had followed me through much of my adult life. My first noticeable breakouts appeared during adolescence. My skin then improved from time to time, but after I turned 20, inflammation became a persistent problem again.
The deep, painful lesions on my lower face and along my jawline bothered me most. Some took weeks to disappear and left red or dark marks behind. My skin occasionally looked relatively calm, but a few new inflamed spots could send me back to avoiding photographs and social occasions where I felt self-conscious.
Over the years, I had tried different topical treatments, changed my skin care and completed courses of treatment that doctors prescribed. Some approaches helped for a while. Others made little difference. Over time, the unpredictability became a source of frustration in its own right. An improvement could raise my hopes, yet I could never rely on that quieter period continuing or know when another round of inflammation would begin.
At another appointment, we discussed scarring risk, my previous treatment results and the possibility of a systemic medicine. My dermatologist explained that isotretinoin reduces oil gland activity and can produce lasting improvement in severe acne or acne that has resisted other treatments.
Before I started, my dermatologist explained the circumstances that could make the medicine unsuitable, the examinations and blood tests I would need, and the adverse reactions that might occur during treatment. We also discussed the risks to a pregnancy, the need to prevent pregnancy during treatment and the requirements of the US iPLEDGE program.
After reviewing my health, completing the tests and meeting the necessary requirements, I began a course that lasted five months.
What I needed to understand before starting isotretinoin
Isotretinoin is a systemic retinoid that clinicians mainly use for severe acne, particularly when other treatments have not provided enough benefit. It acts on several processes involved in acne, including sebum production and the changes that allow hair follicles to become blocked.
The doctor chooses the dose and treatment length for the individual patient. The five months I describe here reflect my own course, rather than a treatment schedule that every person with acne should expect to follow. Some people need more time, and a clinician may adjust treatment according to the response, tolerability and other clinical factors.
Before starting, patients need to tell the dermatologist about every medicine, vitamin and supplement they take. Drug interactions, liver disease, lipid disorders and other health circumstances can affect whether treatment is appropriate and how the clinician monitors it.
For anyone who can become pregnant, isotretinoin poses a serious risk of severe fetal harm. The US iPLEDGE REMS program therefore requires enrollment, confirmation that patients meet the applicable conditions and specific pregnancy prevention measures.
For the relevant patient categories, those measures include pregnancy testing before, during and after treatment, along with requirements concerning contraception or continuous abstinence from sexual activity that could result in pregnancy. Dispensing procedures and the timing of required steps depend on the patient's category.
I understood why those requirements existed and why meeting them formed part of treatment. At the same time, completing the formal safety steps could not tell my doctor everything about how I felt. My physical symptoms and emotional wellbeing still needed attention throughout the course.
Month one: changes that seemed minor at first
During the first few weeks, I kept examining my face in the mirror for signs of improvement. I wanted a result quickly, even though my dermatologist had explained that my skin might not begin clearing straight away.
Dry lips were the first obvious change. The ordinary balm I had previously used a few times a week suddenly did not provide enough relief. My lips began to peel, and painful cracks sometimes developed at the corners of my mouth.
I then noticed irritation around my nose. My skin felt tight after washing, and products I had used before sometimes caused a burning sensation. I had to reconsider the routine I had once followed without much thought. That meant giving up aggressive cleansing, choosing how I washed more carefully and treating moisturizing as a regular part of caring for increasingly sensitive skin.
By the end of the month, contact lenses had become harder to tolerate. Before treatment, I could wear them for most of the working day. Now, after only a few hours, my eyes felt dry and gritty, as though something had caught beneath a lens. I wore glasses more often and discussed the change with my doctor.
My acne had not improved much at that point. Some lesions had become smaller, but new ones kept appearing. That disappointed me, although I knew that a few weeks gave me too little time to judge the treatment's effectiveness.
Month two: side effects began interfering with daily life
In the second month, I noticed changes beyond my skin.
My knees sometimes felt stiff after a long walk. My back tired more quickly after hours at the computer, and physical activities that had previously caused no trouble began to leave my muscles uncomfortable.
At first, I blamed my work schedule and lack of movement. Then I realized that the symptoms had started after treatment began. I told my dermatologist, and we discussed whether the medicine might contribute.
Isotretinoin can cause muscle and joint pain. The intensity varies, and a new symptom does not always mean that treatment must end. A doctor still needs to assess new complaints, particularly when they worsen or limit ordinary activity.
At follow-up, we also discussed my lipid test results. Isotretinoin can raise triglycerides and alter other laboratory findings, so those results matter when a clinician evaluates the safety of a course.
I could not feel anything that would have told me whether my lipid levels had changed. That made laboratory monitoring feel much less abstract: some effects of treatment cannot be recognized without a test.
The inside of my nose also became dry, sometimes with a small amount of blood. The skin on my hands grew sensitive to frequent washing, especially in cold weather.
Taken separately, each problem seemed small enough to manage. Living with several at once felt different. Between my lips, nose, hands and discomfort with movement, the treatment began to occupy far more of my attention than I had expected when I agreed to start.
Month three: my skin improved, but I felt less certain
Around the middle of the course, I began to see sustained improvement in my face. New deep lesions appeared less often, existing spots felt less painful and areas that had almost always looked inflamed began to settle.
This was the change I had wanted from treatment. After years of recurring inflammation, seeing those areas settle gave me a reason to believe that the course could achieve something my earlier treatments had not.
I started wearing less makeup and stopped checking my skin whenever I had a chance. Yet the relief of seeing results came with an uncomfortable sense of tension.
I struggled to work out which changes in how I felt might relate to isotretinoin and which might come from stress or fatigue. At times, I felt irritable, found it harder to concentrate at work and reacted more strongly to small frustrations.
I worried that those feelings might intensify. I began reading other patients' accounts and found very different experiences. Some people had barely noticed adverse effects. Others described physical or psychological difficulties that continued for a long time.
Reading those stories did not always help. After some forum discussions, I listened to my body even more closely and noticed sensations I might otherwise have ignored.
Eventually, I realized that I had reached a point where almost any change in how I felt seemed like a possible threat.
I decided to discuss that pattern in detail at my next appointment instead of trying to determine the cause of every symptom on my own.
Isotretinoin and mental health: a question that needs attention
Researchers continue to investigate possible links between isotretinoin, depression, anxiety and other psychiatric symptoms.
People with acne may already experience considerable distress because of their appearance, social life and the length of time they have lived with the condition. When emotional changes occur, both the disease and the circumstances of treatment need consideration.
Large studies have not established a consistent increase in psychiatric risk across the population of isotretinoin users. Reports of depression, mood changes and suicidal thoughts still deserve a serious response and an individual assessment.
It would be wrong to assume that the medicine causes every episode of anxiety. It would also be wrong to ignore new symptoms simply because research has not established a causal link.
I told my dermatologist about my irritability, periods of anxiety and fatigue. We discussed when they had started, how much they affected my daily life and whether other explanations might contribute.
The conversation itself mattered to me as much as the information I received. I needed help understanding what the symptoms might mean, but I also needed to know that my doctor took them seriously. Feeling anxious or irritable deserved space in the appointment alongside the discussion of my skin.
I continued treatment under medical supervision, knowing that a deterioration in my mental health would require another assessment. Marked mood changes, suicidal thoughts or other concerning symptoms call for immediate medical attention.
Month four: adjusting the way I lived
By the fourth month, I had far fewer inflamed lesions on my face. Small spots still appeared occasionally, but they no longer resembled the deep, painful nodules I had developed before treatment.
Marks from earlier inflammation remained. I understood that controlling active acne would not immediately restore an even skin tone or texture. Some changes might need separate treatment after the course.
Dry lips and skin continued to demand attention. I kept moisturizing products beside my desk, in my bag and at home. During the day, I sometimes needed short breaks to ease the discomfort in my eyes.
I also became more careful with exercise. I stopped trying to train through pain and chose activities that did not leave me with pronounced muscle discomfort afterward.
I had not expected these adjustments to affect so many ordinary habits. From the outside, treatment could look straightforwardly successful: fewer lesions, gradually clearer skin and follow-up visits that took place as planned.
Living through the course meant accounting for my skin, eyes, mucous membranes and joints throughout an ordinary day. The improvement in my face did not remove those other demands, even though someone looking at the clearer skin might see an uncomplicated success.
During this period, I began writing down observations before dermatology appointments. The notes helped me distinguish new complaints from brief sensations and remember the questions I wanted to ask.
I recorded the acne itself, the degree of dryness, discomfort after exercise, changes in mood and any effect on work or sleep.
Writing down my own observations helped me more than an endless search for similar experiences online. It gave the next conversation with my dermatologist a basis in what I had actually noticed, instead of leaving me to compare every sensation with another person's story.
Month five: finishing the course
In the final month, my face looked different from how it had looked at the start. I had far fewer active lesions, and new painful spots had almost stopped troubling me.
For the first time in years, I could wake up without immediately thinking about my skin.
That did not make the treatment feel easy in retrospect. I looked forward to feeling more like myself again, without the constant dryness and discomfort.
Near the end, my dermatologist and I reviewed the result, how I had tolerated the medicine, the necessary test findings and the plan for follow-up.
The decision to finish after five months came from an assessment of my own circumstances. I understood that skin appearance or a date chosen in advance could not, by itself, determine the right treatment length.
After the final dose, the doctor explained which restrictions still applied, which symptoms needed medical attention and how to care for my skin during recovery.
Finishing brought relief. Reaching the end of the prescription did not mean that my skin, eyes and the rest of my body would all feel as they had before treatment on the following day. I understood that recovery would take its own time.
Recovering after isotretinoin
My skin and lips remained dry during the first weeks after I stopped. I continued using gentle cleansers and moisturizers and avoided returning too quickly to the active products I had used before treatment.
Gradually, my lips cracked less often, and washing my face no longer left my skin feeling so tight.
The muscle and joint discomfort also eased. I returned toward my usual exercise routine, increasing the activity gradually.
My eyes took longer to feel comfortable. I still used lubricating products from time to time and paid attention to any worsening symptoms.
Six months after the course ended, my skin remained much clearer than it had been before treatment. I occasionally developed a small, isolated spot, but I no longer experienced the persistent inflammation that had once felt normal.
I do not see that result as a guarantee that acne will never return. Relapse can occur after isotretinoin, and some patients need maintenance therapy or further treatment.
Recovery also varies. Common adverse effects gradually ease for most patients, but some complaints can last longer and need a separate medical assessment.
What I felt was missing during treatment
When I look back at those five months, I think about the different ways doctors and patients can judge the same outcome.
For a dermatologist, fewer inflamed lesions, acceptable laboratory findings and no serious complications provide important evidence that treatment has gone well.
Patients bring other questions to that assessment. Can I work comfortably? Do dry eyes or muscle pain interfere with ordinary activities? Can I sleep, exercise and spend time with people without constantly worrying about my health?
I did not expect my doctor to predict every reaction. I wanted to understand which symptoms we could manage, which might require a change in the plan and when we would need to reconsider continuing treatment.
The adverse-effect information in a leaflet helps, but a long list of medical terms cannot replace a conversation about how those effects may feel in everyday life.
A warning about dry eyes takes on a different meaning when you discover that wearing contact lenses through a working day has become uncomfortable.
Muscle pain presents the same difficulty. The name of the reaction says little about how it might affect training, walking or ordinary tasks.
Those are the kinds of concrete examples I wish we had discussed before I started. They would have helped me connect the medical names on a side-effect list with the ordinary activities I might need to adjust during treatment.
Why monthly appointments need to cover more
Monitoring during isotretinoin treatment serves more than the assessment of acne improvement. The doctor also looks for possible complications, reviews laboratory results and checks that the patient continues to meet the required safety conditions.
A brief standard set of questions may still miss problems that a patient considers too minor to raise. Embarrassment can keep other concerns out of the conversation, particularly when the patient does not know whether a symptom belongs in a dermatology appointment.
The most useful appointments for me covered the effect of symptoms on my daily life as well as the state of my skin.
I think regular questions about exercise tolerance, eye and mucous membrane symptoms, sleep, mood and other new complaints could make those conversations more useful.
Asking whether a patient wants to discuss changing the treatment plan could also make a difference.
Sometimes people stay quiet because they fear losing the improvement they have already achieved, rather than because they have no problems.
I recognize that fear. When your skin finally begins clearing after years of unsuccessful treatment, even thinking about stopping can feel frightening.
Patients need to understand that reporting an adverse effect does not automatically end the prescription. Depending on the clinical situation, the doctor may consider a dose change, additional measures to relieve symptoms or discontinuation when the findings call for it.
How patient support could improve
iPLEDGE has a specific purpose: reducing pregnancy exposure to isotretinoin. It does not provide a complete assessment of every aspect of a patient's quality of life.
I think additional follow-up tools could help clinicians identify difficulties that an ordinary appointment might miss.
A short questionnaire before the visit, for example, could give a patient time to record new physical symptoms, emotional changes and problems carrying out everyday tasks.
The questionnaire should help a patient prepare for the medical conversation. It should neither replace that conversation nor become another formal task to complete before collecting a prescription. Its purpose would be to bring concerns into view while the patient has time to remember them, then give the doctor a starting point for asking further questions.
Assessing psychological wellbeing before treatment could also help. If someone already experiences anxiety, depressive symptoms or another mental health condition, knowing that baseline helps organize the follow-up. It gives the clinician a starting point for comparing earlier difficulties with the concerns a patient describes once treatment begins.
When appropriate, the dermatologist can work with other professionals, including a clinician who provides mental health care.
Patients also need a clear explanation of the difference between established adverse reactions, possible associations and outcomes whose causal relationship with isotretinoin remains uncertain. A listed reaction, an association in a study and a proven cause do not all mean the same thing.
Without that explanation, a person can end up trying to reconcile conflicting information alone and treating every new complaint as evidence of a serious complication.
What I wish I had known before the first dose
If I could go back to the beginning, I would not reject isotretinoin solely because of the difficulties I experienced. I would prepare for the course differently.
Before the first dose, I would make room for a fuller conversation about both kinds of difficulty: the dangerous complications that require urgent attention and the more common symptoms that can change how a person works, rests or exercises through the course.
I would ask which changes I should report immediately, what could relieve dryness of the skin and mucous membranes, and how we would decide whether to continue if unpleasant effects developed.
I wish I had understood earlier that the number of remaining inflamed lesions could not provide the whole measure of successful acne treatment.
Those five months changed my skin. They also made me pay closer attention to my health and taught me to ask questions I had once found uncomfortable.
The reduction in acne mattered. So did learning how much open communication with my dermatologist could change the experience of treatment, from the questions before the first dose to the conversations about symptoms as the course continued.